These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

866 related articles for article (PubMed ID: 24112608)

  • 1. Prognostic significance and therapeutic potential of the activation of anaplastic lymphoma kinase/protein kinase B/mammalian target of rapamycin signaling pathway in anaplastic large cell lymphoma.
    Gao J; Yin M; Zhu Y; Gu L; Zhang Y; Li Q; Jia C; Ma Z
    BMC Cancer; 2013 Oct; 13():471. PubMed ID: 24112608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Study on activation of AKT/mTOR pathway in anaplastic large cell lymphoma].
    Li JF; Li GD; Gu L; Liu WP; Li FY; Liao DY; Ma ZG
    Zhonghua Xue Ye Xue Za Zhi; 2008 Oct; 29(10):649-53. PubMed ID: 19176054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
    Vega F; Medeiros LJ; Leventaki V; Atwell C; Cho-Vega JH; Tian L; Claret FX; Rassidakis GZ
    Cancer Res; 2006 Jul; 66(13):6589-97. PubMed ID: 16818631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapamycin reverses NPM-ALK-induced glucocorticoid resistance in lymphoid tumor cells by inhibiting mTOR signaling pathway, enhancing G1 cell cycle arrest and apoptosis.
    Gu L; Gao J; Li Q; Zhu YP; Jia CS; Fu RY; Chen Y; Liao QK; Ma Z
    Leukemia; 2008 Nov; 22(11):2091-6. PubMed ID: 18685609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.
    Marzec M; Kasprzycka M; Liu X; El-Salem M; Halasa K; Raghunath PN; Bucki R; Wlodarski P; Wasik MA
    Oncogene; 2007 Aug; 26(38):5606-14. PubMed ID: 17353907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EBP2, a novel NPM-ALK-interacting protein in the nucleolus, contributes to the proliferation of ALCL cells by regulating tumor suppressor p53.
    Uchihara Y; Tago K; Tamura H; Funakoshi-Tago M
    Mol Oncol; 2021 Jan; 15(1):167-194. PubMed ID: 33040459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target.
    Werner MT; Zhao C; Zhang Q; Wasik MA
    Blood; 2017 Feb; 129(7):823-831. PubMed ID: 27879258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.
    Christensen JG; Zou HY; Arango ME; Li Q; Lee JH; McDonnell SR; Yamazaki S; Alton GR; Mroczkowski B; Los G
    Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3314-22. PubMed ID: 18089725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Silibinin suppresses NPM-ALK, potently induces apoptosis and enhances chemosensitivity in ALK-positive anaplastic large cell lymphoma.
    Molavi O; Samadi N; Wu C; Lavasanifar A; Lai R
    Leuk Lymphoma; 2016 May; 57(5):1154-62. PubMed ID: 26133723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The heat shock protein-90 co-chaperone, Cyclophilin 40, promotes ALK-positive, anaplastic large cell lymphoma viability and its expression is regulated by the NPM-ALK oncoprotein.
    Pearson JD; Mohammed Z; Bacani JT; Lai R; Ingham RJ
    BMC Cancer; 2012 Jun; 12():229. PubMed ID: 22681779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma.
    Zdzalik D; Dymek B; Grygielewicz P; Gunerka P; Bujak A; Lamparska-Przybysz M; Wieczorek M; Dzwonek K
    J Cancer Res Clin Oncol; 2014 Apr; 140(4):589-98. PubMed ID: 24509625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Blockage of mTOR signaling pathway by rapamycin contributes to inhibition of tumor cell proliferation in ALK-positive lymphoid cell strains].
    Gu L; Li JF; Gao J; Zhu YP; Li Q; Jia CS; Zhou CY; Ma ZG
    Zhonghua Xue Ye Xue Za Zhi; 2008 Oct; 29(10):662-6. PubMed ID: 19176057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway.
    Bai RY; Ouyang T; Miething C; Morris SW; Peschel C; Duyster J
    Blood; 2000 Dec; 96(13):4319-27. PubMed ID: 11110708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of IGF-1R pathway and NPM-ALK G1269A mutation confer resistance to crizotinib treatment in NPM-ALK positive lymphoma.
    Li Y; Wang K; Song N; Hou K; Che X; Zhou Y; Liu Y; Zhang J
    Invest New Drugs; 2020 Jun; 38(3):599-609. PubMed ID: 31177400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sonic hedgehog signaling pathway is activated in ALK-positive anaplastic large cell lymphoma.
    Singh RR; Cho-Vega JH; Davuluri Y; Ma S; Kasbidi F; Milito C; Lennon PA; Drakos E; Medeiros LJ; Luthra R; Vega F
    Cancer Res; 2009 Mar; 69(6):2550-8. PubMed ID: 19244133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signaling.
    Staber PB; Vesely P; Haq N; Ott RG; Funato K; Bambach I; Fuchs C; Schauer S; Linkesch W; Hrzenjak A; Dirks WG; Sexl V; Bergler H; Kadin ME; Sternberg DW; Kenner L; Hoefler G
    Blood; 2007 Nov; 110(9):3374-83. PubMed ID: 17690253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and laboratory characteristics of systemic anaplastic large cell lymphoma in Chinese patients.
    Wang YF; Yang YL; Gao ZF; Zhou CJ; Gregg X; Shi YF; Wang J; Yang XF; Ke XY
    J Hematol Oncol; 2012 Jul; 5():38. PubMed ID: 22769020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. De novo generation of the NPM-ALK fusion recapitulates the pleiotropic phenotypes of ALK+ ALCL pathogenesis and reveals the ROR2 receptor as target for tumor cells.
    Babin L; Darchen A; Robert E; Aid Z; Borry R; Soudais C; Piganeau M; De Cian A; Giovannangeli C; Bawa O; Rigaud C; Scoazec JY; Couronné L; Veleanu L; Cieslak A; Asnafi V; Sibon D; Lamant L; Meggetto F; Mercher T; Brunet E
    Mol Cancer; 2022 Mar; 21(1):65. PubMed ID: 35246138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crizotinib in Combination with Everolimus Synergistically Inhibits Proliferation of Anaplastic Lymphoma Kinase‒Positive Anaplastic Large Cell Lymphoma.
    Xu W; Kim JW; Jung WJ; Koh Y; Yoon SS
    Cancer Res Treat; 2018 Apr; 50(2):599-613. PubMed ID: 28675026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphorylated 4E-binding protein 1 (p-4E-BP1): a novel prognostic marker in human astrocytomas.
    Korkolopoulou P; Levidou G; El-Habr EA; Piperi C; Adamopoulos C; Samaras V; Boviatsis E; Thymara I; Trigka EA; Sakellariou S; Kavantzas N; Patsouris E; Saetta AA
    Histopathology; 2012 Aug; 61(2):293-305. PubMed ID: 22690797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.